EANS-News: Symrise AG and Probi sign joint research and development agreement
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Subtitle: Bundling of expertise in developing new product solutions in the areas of food and beverages, cosmetics, dietary supplements and pharmaceuticals Initial focus on oral care applications with proven health benefits Expanded know-how for accelerated product development in dynamic market segments Company Information Holzminden, December 20, 2012 (euro adhoc) - The German Symrise AG, a leading manufacturer of flavors, fragrances, cosmetics and health ingredients, and the probiotics company Probi AB based in Lund, Sweden, have signed a joint research and development agreement. In response to the growing need for turn-key product solutions with proven health benefits, both companies today announced their plans to collaborate on innovative projects such as in oral health applications. "For Symrise the agreement with Probi is a logical step which, going forward, allows us to meet the growing demand for functional consumer health products even better. Both, in established markets as well as emerging markets, consumers become more and more sensitive to healthy nutrition and a balanced way of life. The highly complementary competencies and strategic innovation agendas of Probi and Symrise will allow us to support our joint customers in their development and marketing efforts, and to grow at an accelerated pace", stated Dr. Heinz-Jürgen Bertram, CEO of Symrise AG. Symrise has expertise in the research, development and manufacturing of food, beverages, cosmetics and pharmaceutical products and sees increasing potential in the health benefits of probiotics. The company combines the ability and the network to perform efficacy screening with the necessary know-how of applying active ingredients. Moreover Symrise holds a globally leading position in the area of oral care. Probi is a trailblazing company that is highly reputed in the research, development and manufacturing of probiotics. It sells some of the most effective gut and immune health probiotics available on the world market. Expanding into new areas such as oral health will offer additional growth prospects for the company. "The globally recognized know-how of Symrise in sensory, active ingredients and applications combined with Probi's long-standing and proprietary expertise in patented probiotics will allow us to develop new consumer products with real health benefits and sensory profiles without compromises," added Michael Oredsson, CEO of Probi AB. Symrise AG currently holds a 14.97% minority share of Probi and may increase this stake in the future. The company is listed on the NASDAQ OMX Nordic exchange in Stockholm. About Symrise Symrise is a global supplier of fragrances, flavorings, cosmetic active ingredients and raw materials as well as functional ingredients. Its clients include manufacturers of perfumes, cosmetics and foods, the pharmaceutical industry and producers of nutritional supplements. Its sales of EUR1.584 billion in 2011 place Symrise among the top four in the global flavors and fragrances market. Headquartered in Holzminden, Germany, the Company is represented in over 35 countries in Europe, Asia, the United States and Latin America. Symrise works with its clients to develop new ideas and market-ready concepts for products that form an indispensable part of everyday life. In doing so, Symrise combines its insights into consumer trends with cutting-edge technologies, focusing on innovative trend and lifestyle products that have additional practical value for the consumer. www.Symrise.com About Probi Probi is a leading player in the probiotic research and the development of efficient and well-documented probiotics. The research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi's customers are leading companies in the functional foods and consumer healthcare business areas. Total income for 2011 was MSEK 95.0. Probi's share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 4,500 shareholders. www.probi.com. Contact: Symrise AG Bernhard Kott Phone: +49 (0)5531 90-1721 E-mail: bernhard.kott@symrise.com Probi AG Michael Oredsson Phone: +46 46 286 23 E-mail: michael.oredsson@probi.se Further inquiry note: Pressekontakt Bernhard Kott Tel. +49 (0)5531 90-1721 bernhard.kott@symrise.com Phone: +46 46 286 23 end of announcement euro adhoc -------------------------------------------------------------------------------- company: Symrise AG Mühlenfeldstraße 1 D-37603 Holzminden phone: +49 (0) 5531/90-0 FAX: +49 (0) 5531/90-1649 mail: ir@symrise.com WWW: http://www.symrise.com sector: Chemicals ISIN: DE000SYM9999 indexes: MDAX stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English
Original content of: Symrise AG, transmitted by news aktuell